Navigation Links
Ivivi's PEMF Technology Significantly Improves Neuron Survival in,Parkinson's Disease Model, Study Finds

NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary Pulsed Electromagnetic Field (PEMF) technology, developed by Ivivi Technologies, Inc. (AMEX:II), improved neuron survival in a standard animal cell model of brain inflammation, researchers reported today in a platform presentation at the Bioelectromagnetics Society (BEMS, http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa, Japan. Inflammation is associated with neuron death that occurs in Parkinson's disease and other neurodegenerative conditions in humans. The preliminary data, from studies conducted by Dr. Diana Casper, neurobiologist at Albert Einstein College of Medicine (NY), indicates that certain PEMF therapies could be neuroprotective.

"Dopaminergic neurons, which die in Parkinson's disease, are clearly susceptible to inflammation," said Dr. Diana Casper. "If we could keep sufficient numbers of them alive, we possibly could keep patients from exhibiting the symptoms associated with Parkinson's. In this model, PEMF signals appeared to both reduce levels of inflammation as well as protect neurons from inflammatory effects."

"Dr. Casper's work demonstrated that our PEMF signals doubled neuron survival in cultures that were subjected to inflammation-creating chemical insult," commented Sean Hagberg, Ph.D., Chief Science Officer, Ivivi Technologies. "While the primary pathological events in neurodegenerative conditions such as Parkinson's disease are still unknown, the potential to delay or prevent the death of dopaminergic neurons could provide new opportunities for Ivivi."

Andre' DiMino, Co-CEO, Ivivi Technologies noted, "This neurological study confirms our commitment to develop innovative, non-invasive and non-pharmacologic electrotherapies, targeting fundamental disease processes common to many of the most debilitating and challenging illnesses. Our mission is to expand applications of our proprietary electrotherapeu tic technologies as we intend to continue to develop our technology for this and other areas."

About Ivivi Technologies, Inc.

Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi's research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company's Electroceuticals(TM) have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders.

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the statements related to the preliminary data discussed above. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company's limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company's products to continue to develop, the inability for c ustomers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company's intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company's products and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including the Company's registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.

Contact

Investor Relations:
Cameron Associates
Alison Ziegler or Lester Rosenkrantz, 212-554-5469
Alison@cameronassoc.com
or
Media:
Deanne Eagle, 212-554-5463
Deanne@cameronassoc.com
or
Public Relations:
Avalanche Strategic Communications
Denyse Dabrowski, 201-488-0049
Mobile: 201-916-7122
Denyse@avalanchepr.com


'"/>




Related medicine technology :

1. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
2. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
6. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
7. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/4/2016)... 2016 For hospitals considering enrollment in the ... in the program, the Health Resources and Services Administration,s ... , Mega-Guidance , could have significant impact on plans ... September 2016. Essential Insights , Daniel ... summarizes the Mega-Guidance,s key proposed changes, including a new ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, ... announced it has entered into a settlement agreement ... (SEC) fully resolving the SEC,s investigation into possible ... Under the terms of the settlement agreement, SciClone ... million, including disgorgement, pre-judgment interest and a penalty.  ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King ... colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and can ... For Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco ... micro-needling services in their Napa Valley office. The technique utilizes the body’s own ... Dr. Canales and Dr. Furnas, are part of only a select few cosmetic ...
(Date:2/5/2016)... ... ... After years as an active staff surgeon and having served as the director ... transitioned to chief of the Division of Plastic Surgery at what is now known ... began a second three-year term in January of 2016. , The original selection was ...
(Date:2/5/2016)... ... February 05, 2016 , ... In the fourth quarter ... gathered at the La Valencia Hotel in San Diego, California to discuss changes ... the year’s most outstanding franchise, walking away with the coveted David Wright Award ...
Breaking Medicine News(10 mins):